Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb 8;2(2):CD003971.
doi: 10.1002/14651858.CD003971.pub4.

Methadone for cancer pain

Alexander B Nicholson  1 , Graeme R Watson  1 , Sheena Derry  2 , Philip J Wiffen  2
Affiliations

Methadone for cancer pain

Alexander B Nicholson et al. Cochrane Database Syst Rev. .

Abstract

Background: This is an updated review originally published in 2004 and first updated in 2007. This version includes substantial changes to bring it in line with current methodological requirements. Methadone is a synthetic opioid that presents some challenges in dose titration and is recognised to cause potentially fatal arrhythmias in some patients. It does have a place in therapy for people who cannot tolerate other opioids but should be initiated only by experienced practitioners. This review is one of a suite of reviews on opioids for cancer pain.

Objectives: To determine the effectiveness and tolerability of methadone as an analgesic in adults and children with cancer pain.

Search methods: For this update we searched CENTRAL, MEDLINE, Embase, CINAHL, and clinicaltrials.gov, to May 2016, without language restriction. We also checked reference lists in relevant articles.

Selection criteria: We sought randomised controlled trials comparing methadone (any formulation and by any route) with active or placebo comparators in people with cancer pain.

Data collection and analysis: All authors agreed on studies for inclusion. We retrieved full texts whenever there was any uncertainty about eligibility. One review author extracted data, which were checked by another review author. There were insufficient comparable data for meta-analysis. We extracted information on the effect of methadone on pain intensity or pain relief, the number or proportion of participants with 'no worse than mild pain'. We looked for data on withdrawal and adverse events. We looked specifically for information about adverse events relating to appetite, thirst, and somnolence. We assessed the evidence using GRADE and created a 'Summary of findings' table.

Main results: We revisited decisions made in the earlier version of this review and excluded five studies that were previously included. We identified one new study for this update. This review includes six studies with 388 participants. We did not identify any studies in children.The included studies differed so much in their methods and comparisons that no synthesis of results was feasible. Only one study (103 participants) specifically reported the number of participants with a given level of pain relief, in this case a reduction of at least 20% - similar in both the methadone and morphine groups. Using an outcome of 'no worse than mild pain', methadone was similar to morphine in effectiveness, and most participants who could tolerate methadone achieved 'no worse than mild pain'. Adverse event withdrawals with methadone were uncommon (12/202) and similar in other groups. Deaths were uncommon except in one study where the majority of participants died, irrespective of treatment group. For specific adverse events, somnolence was more common with methadone than with morphine, while dry mouth was more common with morphine than with methadone. None of the studies reported effects on appetite.We judged the quality of evidence to be low, downgraded due to risk of bias and sparse data. For specific adverse events, we considered the quality of evidence to be very low, downgraded due to risk of bias, sparse data, and indirectness, as surrogates for appetite, thirst and somnolence were used.There were no data on the use of methadone in children.

Authors' conclusions: Based on low-quality evidence, methadone is a drug that has similar analgesic benefits to morphine and has a role in the management of cancer pain in adults. Other opioids such as morphine and fentanyl are easier to manage but may be more expensive than methadone in many economies.

PubMed Disclaimer

Conflict of interest statement

ABN: none known; ABN is a palliative care specialist who manages patients with cancer and prescribes methadone.

GRW: none known.

SD: none known.

PW: none known.

Figures

1
1
Study flow diagram
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Beaver 1967 {published data only}
    1. Beaver WT, Wallenstein SL, Houde RW, Rogers A. A clinical comparison of the analgesic effects of methadone and morphine administered intramuscularly, and of orally and parenterally administered methadone. Clinical Pharmacololgy and Therapeutics 1967;8(3):415‐26. [PUBMED: 5338385] - PubMed
Bruera 2004 {published data only}
    1. Bruera E, Palmer JL, Bosnjak S, Rico MA, Moyano J, Sweeney C, et al. Methadone versus morphine as a first‐line strong opioid for cancer pain: a randomized, double‐blind study. Journal of Clinical Oncology 2004;22(1):185‐92. [DOI: 10.1200/JCO.2004.03.172] - DOI - PubMed
Mercadante 1998 {published data only}
    1. Mercadante S, Casuccio A, Agnello A, Serretta R, Calderone L, Barresi L. Morphine versus methadone in the pain treatment of advanced cancer patients followed up at home. Journal of Clinical Oncology 1998;16(11):3656‐61. [PUBMED: 9817288] - PubMed
Mercadante 2008 {published data only}
    1. Mercadante S, Porzio G, Ferrera P, Fulfaro F, Aielli F, Verna L, et al. Sustained‐release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. European Journal of Pain 2008;12:1040‐6. [DOI: 10.1016/j.ejpain.2008.01.013] - DOI - PubMed
Twycross 1977 {published data only}
    1. Twycross R. A comparison of diamorphine with cocaine and methadone (letter). British Journal of Clinical Practice 1977;4:691‐93. [PUBMED: 69292] - PubMed
Ventafridda 1986 {published data only}
    1. Ventafridda V, Ripamonti C, Bianchi M, Sbanotto A, Conno F. A randomized study on oral administration of morphine and methadone in the treatment of cancer pain. Journal of Pain and Symptom Management 1986;1(4):203‐7. [DOI: 10.1016/S0885-3924(86)80042-2] - DOI - PubMed

References to studies excluded from this review

Cubero 2010 {published data only}
    1. Cubero DIG, Giglio A. Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double‐blind, placebo‐controlled study. Supportive Care in Cancer 2010;18(2):235‐42. [DOI: 10.1007/s00520-009-0649-8] - DOI - PubMed
Ferrer‐Brechner 1984 {published data only}
    1. Ferrer‐Brechner T, Ganz P. Combination therapy with ibuprofen and methadone for chronic cancer pain. American Journal of Medicine 1984;77(1A):78‐83. [DOI: 10.1016/S0002-9343(84)80023-6] - DOI - PubMed
Gourlay 1986 {published data only}
    1. Gourlay GK, Cherry DA, Cousins MJ. A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 1986;25(3):297‐312. [DOI: 10.1016/0304-3959(86)90234-4] - DOI - PubMed
Grochow 1989 {published data only}
    1. Grochow L, Sheidler V, Grossman S, Green L, Enterline J. Does intravenous methadone provide longer lasting analgesia than intravenous morphine? A randomised, double blind study. Pain 1989;38(2):151‐7. [DOI: 10.1016/0304-3959(89)90233-9] - DOI - PubMed
Lauretti 2013 {published data only}
    1. Lauretti GR, Rizzo CC, Mattos AL, Rodrigues SW. Epidural methadone results in dose‐dependent analgesia in cancer pain, further enhanced by epidural dexamethasone. British Journal of Cancer 2013;108(2):259‐64. [DOI: 10.1038/bjc.2012.593] - DOI - PMC - PubMed
Matts 1964 {published data only}
    1. Matts SGF, Swan CHF, Wharton BA. Double blind trial of dextromoramide, methadone and pethidine in the treatment of severe pain. Postgraduate Medical Journal 1964;40:103‐5. [PUBMED: 14122903] - PMC - PubMed
Moksnes 2011 {published data only}
    1. Moksnes K, Dale O, Rosland JH, Paulsen O, Klepstad P, Kaasa S. How to switch from morphine or oxycodone to methadone in cancer patients? A randomised clinical phase II trial. European Journal of Cancer 2011;47(16):2463‐70. [DOI: 10.1016/j.ejca.2011.06.047] - DOI - PubMed
Morley 2003 {unpublished data only}
    1. Morley JS, Bridson J, Nash TP, Miles JB, White S, Makin MK. Low‐dose methadone has an analgesic effect in neuropathic pain: a double‐blind randomized controlled crossover trial. Palliative Medicine 2003; Vol. 17, issue 7:576‐87. [PUBMED: 14594148] - PubMed
NCT00573937 {unpublished data only}
    1. Prommer E (lead investigator). Methadone versus morphine for cancer related pain. clinicaltrials.gov/ct2/show/NCT00573937 (accessed 21 April 2016) 2016. [CTG: NCT00573937]
NCT00726830 {unpublished data only}
    1. Fisch MJ (lead investigator). Methadone, morphine, or oxycodone in treating pain in patients with cancer. clinicaltrials.gov/ct2/show/NCT00726830 (accessed 21 April 2016) 2012. [CTG: NCT00726830]
Raptis 2013 {published data only}
    1. Raptis E, Vadalouca A, Stavropoulou E, Argyra E, Melemeni A, Siafaka I. Pregabalin vs. opioids for the treatment of neuropathic cancer pain: a prospective, head‐to‐head, randomized, open‐label study. Pain Practice 2014;14(1):32‐42. [DOI: 10.1111/papr.12045] - DOI - PubMed

Additional references

Bruera 1991
    1. Bruera E, Fainsinger R, Moore M, Thibault R, Spoldi E, Ventafridda V. Local toxicity with subcutaneous methadone. Experience of two centers. Pain 1991;45(2):141‐3. [DOI: 10.1016/0304-3959(91)90179-2] - DOI - PubMed
Bruera 2002
    1. Bruera E, Sweeney C. Methadone use in cancer patients with pain: a review. Journal of Palliative Medicine 2002;5(1):127‐38. [DOI: 10.1089/10966210252785097] - DOI - PubMed
Cruciani 2008
    1. Cruciani RA. Methadone: to ECG or not to ECG.... That is still the question. Journal of Pain and Symptom Management 2008;36(5):545‐52. [DOI: 10.1016/j.jpainsymman.2007.11.003] - DOI - PubMed
Davis 2001
    1. Davis MP, Walsh D. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Supportive Care in Cancer 2001;9(2):73‐83. [DOI: 10.1007/s005200000180] - DOI - PubMed
DH 2013
    1. Anon. More care, less pathway. A review of the Liverpool Care Pathway. Report by Baroness Julia Neuberger (Chair), available at www.gov.uk/government/uploads/system/uploads/attachment_data/file/212450... (accessed 21 April 2016).
Fainsinger 1993
    1. Fainsinger R, Schoeller T, Bruera E. Methadone in the management of cancer pain: a review. Pain 1993;51(2):137‐47. [DOI: 10.1016/0304-3959(93)90125-9] - DOI - PubMed
Gannon 1997
    1. Gannon C. The use of methadone in the care of the dying. European Journal of Palliative Care 1997;4(5):152‐8.
Good 2014
    1. Good P, Afsharimani B, Movva R, Haywood A, Khan S Hardy J. Therapeutic challenges in cancer pain management: a systematic review of methadone. Journal of Pain and Palliative Care Pharmacotherapy 2014;28(3):197‐205. [DOI: 10.3109/15360288.2014.938883] - DOI - PubMed
Gorman 1997
    1. Gorman AL, Elliott KJ, Inturrisi CE. The d‐ and l‐isomers of methadone bind to the non‐competitive site on the N‐methyl‐D‐aspartate (NMDA) receptor in rat forebrain and spinal cord. Neuroscience Letters 1997;223(1):5‐8. - PubMed
Graner 2016
    1. Graner KM, Rolim GS, Moraes AB, Padovani CR, Lopes MA, Santos‐Silva AR, et al. Feelings, perceptions, and expectations of patients during the process of oral cancer diagnosis. Support Care Cancer 2016;24:2323‐32. [DOI: 10.1007/s00520-015-3030-0] - DOI - PubMed
Guyatt 2013a
    1. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso‐Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology 2013;66(2):151‐7. [DOI: 10.1016/j.jclinepi.2012.01.006] - DOI - PubMed
Guyatt 2013b
    1. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables‐binary outcomes. Journal of Clinical Epidemiology 2013;66(2):158‐72. [DOI: 10.1016/j.jclinepi.2012.01.012] - DOI - PubMed
Hanks 1998
    1. Hanks GWC, Cherny N. Opioid analgesic therapy. In: Doyle D, Hanks GWC, MacDonald N editor(s). Oxford Textbook of Palliative Medicine. Oxford: Oxford University Press, 1998:331‐51.
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Ma 2016
    1. Ma H, Liu Y, Huang L, Zeng XT, Jin SH, Yue GJ, et al. The adverse events of oxycodone in cancer‐related pain: a systematic review and meta‐analysis of randomized controlled trials. Medicine (Baltimore) 2016;95(15):e3341. [DOI: 10.1097/MD.0000000000003341] - DOI - PMC - PubMed
Mathew 1999
    1. Mathew P, Storey P. Subcutaneous methadone in terminally ill patients: manageable local toxicity. Journal of Pain and Symptom Management 1999;18(1):49‐52. [DOI: 10.1016/S0885-3924(99)00020-2] - DOI - PubMed
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed1000097] - DOI - PMC - PubMed
Payne 1998
    1. Payne R, Gonzales GR. Pathophysiology of pain in cancer and other terminal diseases. In: Doyle D, Hanks GWC, MacDonald N editor(s). Oxford Textbook of Palliative Medicine. Oxford: Oxford University Press, 1998:299‐310.
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Ripamonti 1997
    1. Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. Pain 1997;70(2‐3):109‐15. [DOI: 10.1016/S0304-3959(96)03286-1] - DOI - PubMed
Twycross 1998
    1. Twycross R, Wilcock A, Thorpe S. Palliative Care Formulary. Oxford: Radcliffe Medical Press, 1998.
Twycross 2014
    1. Twycross R, Wilcock A (Eds). PCF5 Palliative Care Formulary. Fifth. Nottingham: palliativedrugs.com Ltd, 2014. [ISBN: 978‐0‐9552547‐9‐6]
van den Beuken‐van Everdingen 2007
    1. Beuken‐van Everdingen MH, Rijke JM, Kessels AG, Schouten HC, Kleef M, Patijn J. High prevalence of pain in patients with cancer in a large population‐based study in The Netherlands. Pain 2007;132:312‐20. - PubMed
van den Beuken‐van Everdingen 2013
    1. Beuken‐van Everdingen MH, Geurts JW, Patijn J. Prolonged QT interval by methadone: relevance for daily practice? A prospective study in patients with cancer and noncancer pain. Journal of Opioid Management 2013;9(4):263‐7. [DOI: 10.5055/jom.2013.0167] - DOI - PubMed
Ventafridda 1987
    1. Ventafridda V, Tamburini M, Caraceni A, Conno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer 1987;59(4):850‐6. [PUBMED: 3802043] - PubMed
Weschules 2008
    1. Weschules DJ, Bain KT, Richeimer S. Actual and potential drug interactions associated with methadone. Pain Medicine 2008;9(3):315‐44. [DOI: 10.1111/j.1526-4637.2006.00289.x] - DOI - PubMed
Wiffen 2014
    1. Wiffen PJ, Derry S, Moore RA. Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD011056.pub2] - DOI - PMC - PubMed

References to other published versions of this review

Nicholson 2002
    1. Nicholson A, Davies A, Reid C. Methadone for cancer pain. Cochrane Database of Systematic Reviews 2002, Issue 11. [DOI: 10.1002/14651858.CD003971] - DOI
Nicholson 2004
    1. Nicholson AB. Methadone for cancer pain. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD003971.pub2] - DOI - PubMed
Nicholson 2007
    1. Nicholson AB. Methadone for cancer pain. Cochrane Database of Systematic Reviews 2007, Issue 10. [DOI: 10.1002/14651858.CD003971.pub3] - DOI - PubMed

Publication types

LinkOut - more resources